New vaginal progesterone device tested for safety and ease of use

NCT ID NCT07136922

Recruiting now Symptom relief Sponsor: Calla Lily Clinical Care Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new vaginal product (Callavid) that delivers 400mg of progesterone to women with luteal phase insufficiency, a condition that can affect fertility. The study compares it to an existing pessary to see if it is safe, well-tolerated, and easy to use. 20 non-pregnant women aged 18-45 with a history of miscarriage will participate in a crossover design, using both products and reporting their experiences.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUTEAL PHASE INSUFFIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

progesterone resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUTEAL PHASE INSUFFIENCY PROGESTERONE DELIVERY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University Hospitals Coventry & Warwickshire NHS Trust
RECRUITING

Coventry, CV2 2DX, United Kingdom

Contact Phone: •••-•••-•••• Email: •••••@•••••